A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.

@article{Ma2010ATA,
  title={A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.},
  author={Wen Wee Ma and Joseph M. Herman and Antonio J. Jimeno and Daniel A. Laheru and Wells A. Messersmith and Christopher L. Wolfgang and John L. Cameron and T M Pawlik and Ross C. Donehower and Michelle A. Rudek and Maartje Hidalgo},
  journal={Translational oncology},
  year={2010},
  volume={3 6},
  pages={373-9}
}
BACKGROUND Erlotinib is approved for the treatment of advanced pancreas cancer. We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic cancer patients. The pharmacokinetic profile of this… CONTINUE READING